Calverton, MD, United States
Calverton, MD, United States

Time filter

Source Type

Brinton L.A.,U.S. National Cancer Institute | Scoccia B.,University of Illinois at Chicago | Moghissi K.S.,Wayne State University | Westhoff C.L.,Columbia University | And 4 more authors.
Cancer Epidemiology Biomarkers and Prevention | Year: 2014

Background: Although fertility drugs stimulate ovulation and raise estradiol levels, their effect on breast cancer risk remains unresolved. Methods: An extended follow-up was conducted among a cohort of 12,193 women evaluated for infertility between 1965 and 1988 at five U.S. sites. Follow-up through 2010 was achieved for 9,892 women (81.1% of the eligible population) via passive as well as active (questionnaires) means. Cox regression determined HRs and 95% confidence intervals (CI) for fertility treatments adjusted for breast cancer risk factors and causes of infertility. Results: During 30.0 median years of follow-up (285,332 person-years), 749 breast cancers were observed. Ever use of clomiphene citrate among 38.1% of patients was not associated with risk (HR = 1.05; 95% CI, 0.90-1.22 vs. never use). However, somewhat higher risks were seen for patients who received multiple cycles, with the risk for invasive cancers confirmed by medical records being significantly elevated (HR = 1.69; 95% CI, 1.17-2.46). This risk remained relatively unchanged after adjustment for causes of infertility and multiple breast cancer predictors. Gonadotropins, used by 9.6% of patients, mainly in conjunction with clomiphene, showed inconsistent associations with risk, although a significant relationship of use with invasive cancers was seen among women who remained nulligravid (HR = 1.98; 95% CI, 1.04-3.60). Conclusions: Although the increased breast cancer risk among nulligravid women associated with gonadotropins most likely reflects an effect of underlying causes of infertility, reasons for the elevated risk associated with multiple clomiphene cycles are less clear. Impact: Given our focus on a relatively young population, additional evaluation of long-term fertility drug effects on breast cancer is warranted. ©2014 AACR.


Brinton L.A.,U.S. National Cancer Institute | Moghissi K.S.,Wayne State University | Scoccia B.,University of Illinois at Chicago | Lamb E.J.,Stanford University | And 4 more authors.
Fertility and Sterility | Year: 2015

Objective To examine the relationship of ovulation-stimulating drugs to risk of cancers other than breast and gynecologic malignancies. Design Retrospective cohort study, with additional follow-up since initial report. Setting Reproductive endocrinology practices. Patient(s) Among a cohort of 12,193 women evaluated for infertility between 1965 and 1988, a total of 9,892 women (81.1% of the eligible population) were followed through 2010, via passive and active (questionnaire) approaches. Intervention(s) None. Main Outcome Measure(s) Hazard ratios (HRs) and 95% confidence intervals (CIs) for various fertility treatment parameters for select cancers. Result(s) During 30.0 median years of follow-up (285,332 person-years), 91 colorectal cancers, 84 lung cancers, 55 thyroid cancers, and 70 melanomas were diagnosed among study subjects. Clomiphene citrate (CC), used by 38.1% of patients, was not associated with colorectal or lung cancer risks, but was related significantly to melanoma (HR = 1.95; 95% CI: 1.18-3.22), and non-significantly to thyroid cancer risks (HR = 1.57; 95% CI: 0.89-2.75). The highest melanoma risks were seen among those with the lowest drug exposure levels, but thyroid cancer risk was greatest among the heavily exposed patients (HR = 1.96; 95% CI: 0.92-4.17 for those receiving >2,250 mg). Clomiphene citrate-associated risks for thyroid cancer were somewhat higher among nulligravid, compared with gravid, women, but did not differ according to distinct causes of infertility. Gonadotropins, used by only 9.7% of subjects, were not related to risk of any of the assessed cancers. Conclusion(s) Our results provide support for continued monitoring of both melanoma and thyroid cancer risk among patients receiving fertility drugs. © 2015 Published by Elsevier Inc. on behalf of the American Society for Reproductive Medicine.


Trademark
IMS Inc. | Date: 2012-08-23

Disposable latex and nitrile gloves for general use.


Trademark
Ims Company | Date: 2014-03-24

INDUSTRIAL LUBRICANTS AND GREASES.


Trademark
IMS Inc. | Date: 2013-05-02

Medical examination gloves.


Trademark
IMS Company | Date: 2015-08-24

Ready-to-use chemical purging compounds in powder or liquid form for use in extruders, in cylinders of injection molding machines, and in plastics processing equipment.


Trademark
IMS Company | Date: 2011-09-13

CHEMICAL PREPARATIONS FOR USE IN CONJUNCTION WITH MOLDING MACHINES FOR MOLDING PLASTIC PARTS, NAMELY, CHEMICAL PREPARATIONS APPLIED TO A MOLD TO FACILITATE RELEASE OF THE PLASTIC PARTS FROM THE MOLD; CHEMICAL PRESERVATIVES FOR USE IN PREVENTING CORROSION IN PLASTIC INJECTION MOLDS; AND CHEMICAL PREPARATIONS APPLIED TO A HEATING CYLINDER ADJACENT A MOLD TO IMPROVE HEAT TRANSFER FROM HEATER BANDS TO THE HEATING CYLINDER. CHEMICAL PREPARATIONS FOR USE IN POLISHING PLASTIC INJECTION MOLDS; CHEMICAL PREPARATIONS FOR USE IN CLEANING HEATING CYLINDERS. INDUSTRIAL MACHINERY AND AUXILIARY EQUIPMENT, NAMELY, MATERIAL HANDLING MACHINERY, MIXERS, DRYERS, DE-GATERS, PART/RUNNER SEPARATORS AND GRANULATORS, PURGE VALVES AND DE-SCALERS USED IN CONJUNCTION WITH MOLDING MACHINES FOR MOLDING PLASTIC PARTS; AND REPLACEMENT PARTS FOR MOLDING MACHINES, NAMELY, NOZZLES. TEMPERATURE CONTROLLERS FOR USE IN CONJUNCTION WITH MOLDING MACHINES FOR MOLDING PLASTIC PARTS.


Trademark
IMS Inc. | Date: 2017-01-23

Medical examination gloves. Disposable latex gloves for general use.


Ims

Trademark
IMS Company | Date: 2012-04-24

Plastic injection molding machinery and parts and accessories therefor, namely, plastic tumblers and granulators, screws and barrels, nozzles and nozzle accessories, nozzle tips, nozzle thread adapters, metal trap adapters, screw tips, screw tip sealing rings, heater bands, cartridge heaters, mold clamps and sweeps, plastic gate cutters, molded part conveyors and separators, mold circulators, material handling equipment for use in loading and conveying plastic materials into plastic processing machines, material mixing equipment, hopper dryers and plastic drying ovens for drying plastic resins, granulator regrind loaders, and hopper dryer dispersion heads. Temperature and voltage controllers and indicators for plastic injection molding machines, blow molding machines, and extrusion molding machines; current sensors, electronic feedback controllers, surface pyrometers, granulator catch bin magnets, hopper magnets, dew point meters and monitors, tie bar strain testing gauges, molded part weighing scales, voltage testers, and process timers; thermocouples.


Trademark
IMS Company | Date: 2012-08-17

INDUSTRIAL LUBRICANTS AND GREASES.

Loading IMS Inc collaborators
Loading IMS Inc collaborators